Treating diabetes today with gliclazide MR: a matter of numbers. - Wikidata - thesis-toulmin - TriplyDB

Treating diabetes today with gliclazide MR: a matter of numbers.

Treating diabetes today with gliclazide MR: a matter of numbers.

http://www.wikidata.org/entity/Q37961238

about

Synthetic (+)-antroquinonol exhibits dual actions against insulin resistance by triggering AMP kinase and inhibiting dipeptidyl peptidase IV activities Rutin potentiates insulin receptor kinase to enhance insulin-dependent glucose transporter 4 translocation.

P2860

Q34795679-4ABFFE9E-87C2-4858-9F54-B2ED9BA80054 Q54364787-68233BC5-292D-432E-A034-55EBA44AF5E6

P2860

Treating diabetes today with gliclazide MR: a matter of numbers.

http://www.wikidata.org/entity/Q37961238

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Treating diabetes today with gliclazide MR: a matter of numbers.

@en

Treating diabetes today with gliclazide MR: a matter of numbers.

@nl

type

label

Treating diabetes today with gliclazide MR: a matter of numbers.

@en

Treating diabetes today with gliclazide MR: a matter of numbers.

@nl

prefLabel

Treating diabetes today with gliclazide MR: a matter of numbers.

@en

Treating diabetes today with gliclazide MR: a matter of numbers.

@nl

P1433

Q37961238-EEDBD63E-E79B-41A2-8C52-4F868B24623C

P1476

Q37961238-FC1AA725-F29A-4402-8BD1-5FC27FE9EEB1

P2093

Q37961238-6A208411-A466-4923-A03F-D599831541C9

P2860

Q37961238-0602472B-975C-48BB-8AD7-525630C999FA

Q37961238-08BAC023-C1E2-43F9-8329-50D6459274C7

Q37961238-0C0CEFB6-1D52-48F1-9E5E-0FBD3C568918

Q37961238-0FAFFAEB-63A8-4A6C-918A-1BC69AD8CBA4

Q37961238-193EAEF0-0570-40E5-AB28-E9AB68110E03

Q37961238-1E8CD7D1-178D-4A7E-9195-4A542BDB9A0F

Q37961238-204523BF-787E-4D36-B527-DCA512A5C724

Q37961238-38F5888E-71FC-4F94-B5B5-266E92B93FE1

Q37961238-3BF6161C-E44C-4160-9D85-7ACE09F8EB4A

Q37961238-405BBED1-58E5-4806-B9A3-E28F82465A24

P304

Q37961238-2F5B5D24-B0BF-45EA-B76B-CA07D231C977

P31

Q37961238-FDB16698-D459-4748-B3DD-C674ACB2DCDD

P356

Q37961238-339D9FE7-0055-46D6-A193-EE69AF2FA45A

P478

Q37961238-52095E1F-4E65-4A4B-9991-2EB59D37AB92

P577

Q37961238-644193DB-0042-4D5E-A117-F538551CF9D0

P5875

Q37961238-6426C247-3E24-4143-9157-396BE29CE8E0

P698

Q37961238-2A3782D6-4C9C-4B95-BDDF-0D0DE33551A2

P356

J.1463-1326.2011.01508.X

P1433

Diabetes, Obesity and Metabolism

P1476

Treating diabetes today with gliclazide MR: a matter of numbers.

@en

P2093

A Avogaro

http://www.w3.org/2001/XMLSchema#string

P2860

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

Oxidative stress as a major culprit in kidney disease in diabetes

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Glucose control and vascular complications in veterans with type 2 diabetes

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

P304

14-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1463-1326.2011.01508.X

http://www.w3.org/2001/XMLSchema#string

P478

14 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221718116

http://www.w3.org/2001/XMLSchema#string

P698

22118706

http://www.w3.org/2001/XMLSchema#string